Leyden Labs

Biotech · Leiden, NL · leydenlabs.com

Clinical-stage biotech developing nasal sprays for protection against respiratory infections.

Founders

Koenraad Wiedhaup (Netherlands · ♂) — A Dutch life scientist and former McKinsey life-sciences partner, he co-founded Leyden Labs in 2020 to develop intranasal antibody medicines for pandemic preparedness, serving as CEO.
Jaap Goudsmit (Netherlands · ♂) — A virologist and Crucell co-founder, he brought deep vaccine science to co-found Leyden Labs and tackle respiratory viruses at the mucosal level.
Ronald Brus (Netherlands · ♂) — A serial biotech entrepreneur and former Crucell CEO who reunited with his Crucell colleagues to co-found Leyden Labs for pandemic-ready intranasal medicines.
Dinko Valerio (Netherlands · ♂) — A founder of vaccine pioneer Crucell, he joined the Crucell veteran team to co-found Leyden Labs and pursue broad-spectrum antiviral protection.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Jun 2026	Funding round Leyden Labs raised funding, following selection for the EIC STEP Scale Up programme, to advance its intranasal protection platform through clinical development.	$46M
Oct 2025	Funding round Leyden Labs secured €30 million in equity from the EIC Fund and Invest-NL to advance clinical development of its pan-influenza nasal spray.	$34.8M
Feb 2022	Series B Amsterdam biotech Leyden Labs raised a 140M dollar Series B led by Casdin Capital and GV, with SoftBank Vision Fund 2, Invus and F-Prime Capital.	$124.2M
Mar 2021	Series A Amsterdam biotech Leyden Labs raised a EUR40M Series A led by GV, with F-Prime Capital, Casdin Capital and Brook Byers.	$40M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.